HER2-POSITIVE COLORECTAL CANCER
Clinical trials for HER2-POSITIVE COLORECTAL CANCER explained in plain language.
Never miss a new study
Get alerted when new HER2-POSITIVE COLORECTAL CANCER trials appear
Sign up with your email to follow new studies for HER2-POSITIVE COLORECTAL CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental HER2 cancer drug trial halted early
Disease control TerminatedThis was an early-phase study testing a new drug called XMT-2056 in people with advanced solid tumors that have a protein called HER2. The trial aimed to find a safe dose and check for side effects. It was terminated early, so the full results are not available.
Matched conditions: HER2-POSITIVE COLORECTAL CANCER
Phase: PHASE1 • Sponsor: Day One Biopharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Experimental cancer combo trial halted early – what it means for patients
Disease control TerminatedThis early-stage trial tested a new drug called BDC-1001, alone or with the immunotherapy nivolumab, in 175 people with advanced HER2-positive cancers (like breast, colorectal, and stomach cancers) that had stopped responding to other treatments. The study aimed to check safety a…
Matched conditions: HER2-POSITIVE COLORECTAL CANCER
Phase: PHASE1, PHASE2 • Sponsor: Bolt Biotherapeutics, Inc. • Aim: Disease control
Last updated Jun 26, 2026 17:13 UTC